AAPL327.74+1.15 (+0.35%) ▲|ABBV256.10+2.72 (+1.07%) ▲|ABT99.67-1.99 (-1.96%) ▼|ACN140.86-3.87 (-2.67%) ▼|ADBE227.16-7.58 (-3.23%) ▼|AMAT564.55+38.85 (+7.39%) ▲|AMD544.43+40.86 (+8.11%) ▲|AMGN366.24+2.07 (+0.57%) ▲|AMT163.39-3.67 (-2.20%) ▼|AMZN247.55-2.44 (-0.98%) ▼|AVGO386.50+8.34 (+2.21%) ▲|AXP350.79-1.14 (-0.32%) ▼|BA204.80-4.68 (-2.23%) ▼|BAC61.22+0.80 (+1.32%) ▲|BKNG179.40-0.05 (-0.03%) ▼|BLK1,038.24-15.87 (-1.51%) ▼|BMY60.93+0.77 (+1.28%) ▲|BNY158.89+1.96 (+1.25%) ▲|BRK-B489.65-1.60 (-0.33%) ▼|C132.84+4.12 (+3.20%) ▲|CAT889.97+25.67 (+2.97%) ▲|CL90.50-1.43 (-1.56%) ▼|CMCSA23.81+0.03 (+0.13%) ▲|COF206.22-0.55 (-0.27%) ▼|COP117.50+1.82 (+1.57%) ▲|COST929.22-6.58 (-0.70%) ▼|CRM170.06-3.73 (-2.15%) ▼|CSCO112.18+1.48 (+1.34%) ▲|CVS110.60+2.99 (+2.78%) ▲|CVX191.07+1.36 (+0.72%) ▲|DE586.88+0.88 (+0.15%) ▲|DHR179.01-22.10 (-10.99%) ▼|DIS96.14-0.27 (-0.28%) ▼|DUK125.91+0.06 (+0.05%) ▲|EMR139.26+2.68 (+1.96%) ▲|FDX315.19+8.97 (+2.93%) ▲|GD367.73-2.87 (-0.77%) ▼|GE340.70-0.60 (-0.18%) ▼|GEV1,078.81-0.37 (-0.03%) ▼|GILD130.28-2.93 (-2.20%) ▼|GM79.52+3.72 (+4.91%) ▲|GOOG346.19-5.18 (-1.47%) ▼|GOOGL347.15-4.84 (-1.38%) ▼|GS1,085.56+30.53 (+2.89%) ▲|HD331.60-1.44 (-0.43%) ▼|HON229.86+3.68 (+1.63%) ▲|IBM210.50-2.50 (-1.17%) ▼|INTC105.45+8.39 (+8.64%) ▲|INTU289.92-3.90 (-1.33%) ▼|ISRG350.06-3.11 (-0.88%) ▼|JNJ250.61+1.79 (+0.72%) ▲|JPM345.23+6.36 (+1.88%) ▲|KO81.97-0.15 (-0.18%) ▼|LIN505.03-7.02 (-1.37%) ▼|LLY1,175.41+28.51 (+2.49%) ▲|LMT507.09-2.45 (-0.48%) ▼|LOW203.51-1.20 (-0.59%) ▼|LRCX322.00+15.24 (+4.97%) ▲|MA538.30-9.14 (-1.67%) ▼|MCD263.91-3.73 (-1.39%) ▼|MDLZ59.86-0.41 (-0.68%) ▼|MDT82.35-0.94 (-1.13%) ▼|META643.81-2.04 (-0.32%) ▼|MMM170.76+11.65 (+7.32%) ▲|MO72.99-1.67 (-2.24%) ▼|MRK126.26+1.86 (+1.50%) ▲|MS216.40+5.46 (+2.59%) ▲|MSFT397.75-4.54 (-1.13%) ▼|MU970.82+105.36 (+12.17%) ▲|NEE87.93-0.07 (-0.08%) ▼|NFLX68.67+1.07 (+1.58%) ▲|NKE42.96-0.51 (-1.17%) ▼|NOW102.06-2.64 (-2.52%) ▼|NVDA207.29+4.01 (+1.97%) ▲|ORCL127.05+5.67 (+4.67%) ▲|PEP135.00-0.46 (-0.34%) ▼|PFE24.94+0.19 (+0.77%) ▲|PG148.10-1.03 (-0.69%) ▼|PLTR132.66-2.19 (-1.62%) ▼|PM188.04-4.68 (-2.43%) ▼|QCOM173.50+3.18 (+1.87%) ▲|RTX193.67-0.77 (-0.40%) ▼|SBUX104.45-0.36 (-0.34%) ▼|SCHW99.96-2.58 (-2.52%) ▼|SO93.85-0.61 (-0.65%) ▼|SPG226.79-1.40 (-0.61%) ▼|T22.26+0.31 (+1.41%) ▲|TMO523.46-2.77 (-0.53%) ▼|TMUS190.77-4.87 (-2.49%) ▼|TSLA378.93+9.36 (+2.53%) ▲|TXN291.30+7.23 (+2.55%) ▲|UBER71.55-0.62 (-0.86%) ▼|UNH436.35+14.80 (+3.51%) ▲|UNP293.13-3.12 (-1.05%) ▼|UPS116.34+3.19 (+2.82%) ▲|USB63.71+0.57 (+0.90%) ▲|V355.82-4.75 (-1.32%) ▼|VZ43.78+0.28 (+0.64%) ▲|WFC87.74+1.41 (+1.63%) ▲|WMT110.39-1.81 (-1.61%) ▼|XOM151.71+3.35 (+2.26%) ▲|AAPL327.74+1.15 (+0.35%) ▲|ABBV256.10+2.72 (+1.07%) ▲|ABT99.67-1.99 (-1.96%) ▼|ACN140.86-3.87 (-2.67%) ▼|ADBE227.16-7.58 (-3.23%) ▼|AMAT564.55+38.85 (+7.39%) ▲|AMD544.43+40.86 (+8.11%) ▲|AMGN366.24+2.07 (+0.57%) ▲|AMT163.39-3.67 (-2.20%) ▼|AMZN247.55-2.44 (-0.98%) ▼|AVGO386.50+8.34 (+2.21%) ▲|AXP350.79-1.14 (-0.32%) ▼|BA204.80-4.68 (-2.23%) ▼|BAC61.22+0.80 (+1.32%) ▲|BKNG179.40-0.05 (-0.03%) ▼|BLK1,038.24-15.87 (-1.51%) ▼|BMY60.93+0.77 (+1.28%) ▲|BNY158.89+1.96 (+1.25%) ▲|BRK-B489.65-1.60 (-0.33%) ▼|C132.84+4.12 (+3.20%) ▲|CAT889.97+25.67 (+2.97%) ▲|CL90.50-1.43 (-1.56%) ▼|CMCSA23.81+0.03 (+0.13%) ▲|COF206.22-0.55 (-0.27%) ▼|COP117.50+1.82 (+1.57%) ▲|COST929.22-6.58 (-0.70%) ▼|CRM170.06-3.73 (-2.15%) ▼|CSCO112.18+1.48 (+1.34%) ▲|CVS110.60+2.99 (+2.78%) ▲|CVX191.07+1.36 (+0.72%) ▲|DE586.88+0.88 (+0.15%) ▲|DHR179.01-22.10 (-10.99%) ▼|DIS96.14-0.27 (-0.28%) ▼|DUK125.91+0.06 (+0.05%) ▲|EMR139.26+2.68 (+1.96%) ▲|FDX315.19+8.97 (+2.93%) ▲|GD367.73-2.87 (-0.77%) ▼|GE340.70-0.60 (-0.18%) ▼|GEV1,078.81-0.37 (-0.03%) ▼|GILD130.28-2.93 (-2.20%) ▼|GM79.52+3.72 (+4.91%) ▲|GOOG346.19-5.18 (-1.47%) ▼|GOOGL347.15-4.84 (-1.38%) ▼|GS1,085.56+30.53 (+2.89%) ▲|HD331.60-1.44 (-0.43%) ▼|HON229.86+3.68 (+1.63%) ▲|IBM210.50-2.50 (-1.17%) ▼|INTC105.45+8.39 (+8.64%) ▲|INTU289.92-3.90 (-1.33%) ▼|ISRG350.06-3.11 (-0.88%) ▼|JNJ250.61+1.79 (+0.72%) ▲|JPM345.23+6.36 (+1.88%) ▲|KO81.97-0.15 (-0.18%) ▼|LIN505.03-7.02 (-1.37%) ▼|LLY1,175.41+28.51 (+2.49%) ▲|LMT507.09-2.45 (-0.48%) ▼|LOW203.51-1.20 (-0.59%) ▼|LRCX322.00+15.24 (+4.97%) ▲|MA538.30-9.14 (-1.67%) ▼|MCD263.91-3.73 (-1.39%) ▼|MDLZ59.86-0.41 (-0.68%) ▼|MDT82.35-0.94 (-1.13%) ▼|META643.81-2.04 (-0.32%) ▼|MMM170.76+11.65 (+7.32%) ▲|MO72.99-1.67 (-2.24%) ▼|MRK126.26+1.86 (+1.50%) ▲|MS216.40+5.46 (+2.59%) ▲|MSFT397.75-4.54 (-1.13%) ▼|MU970.82+105.36 (+12.17%) ▲|NEE87.93-0.07 (-0.08%) ▼|NFLX68.67+1.07 (+1.58%) ▲|NKE42.96-0.51 (-1.17%) ▼|NOW102.06-2.64 (-2.52%) ▼|NVDA207.29+4.01 (+1.97%) ▲|ORCL127.05+5.67 (+4.67%) ▲|PEP135.00-0.46 (-0.34%) ▼|PFE24.94+0.19 (+0.77%) ▲|PG148.10-1.03 (-0.69%) ▼|PLTR132.66-2.19 (-1.62%) ▼|PM188.04-4.68 (-2.43%) ▼|QCOM173.50+3.18 (+1.87%) ▲|RTX193.67-0.77 (-0.40%) ▼|SBUX104.45-0.36 (-0.34%) ▼|SCHW99.96-2.58 (-2.52%) ▼|SO93.85-0.61 (-0.65%) ▼|SPG226.79-1.40 (-0.61%) ▼|T22.26+0.31 (+1.41%) ▲|TMO523.46-2.77 (-0.53%) ▼|TMUS190.77-4.87 (-2.49%) ▼|TSLA378.93+9.36 (+2.53%) ▲|TXN291.30+7.23 (+2.55%) ▲|UBER71.55-0.62 (-0.86%) ▼|UNH436.35+14.80 (+3.51%) ▲|UNP293.13-3.12 (-1.05%) ▼|UPS116.34+3.19 (+2.82%) ▲|USB63.71+0.57 (+0.90%) ▲|V355.82-4.75 (-1.32%) ▼|VZ43.78+0.28 (+0.64%) ▲|WFC87.74+1.41 (+1.63%) ▲|WMT110.39-1.81 (-1.61%) ▼|XOM151.71+3.35 (+2.26%) ▲|
23.5 C
New York
Wednesday, July 22, 2026

Tag: clinical trial

newssourceFORcompanyinformationcontent1releasesmarket

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Sheba Medical Center, which is ranked the #7 hospital in the world,...

BOND Trial Aims to Improve Support for Families Facing Congenital Heart Disease

Multicenter study, conducted through the Pediatric Heart Network — and co-led by Cincinnati Children's — will test new ways to strengthen parent well-being, bonding...

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new...

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of...

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of...

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade...

Siren Biotechnology awarded $8M in grant funding from the California Institute for Regenerative Medicine (CIRM) to support clinical development of SRN-101

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed.

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at...

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participantsOvarian...

Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia

SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers